Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
27,196,692
-
Number of holders
-
51
-
Total 13F shares, excl. options
-
10,562,398
-
Shares change
-
+2,140,100
-
Total reported value, excl. options
-
$37,917,223
-
Value change
-
+$7,583,819
-
Put/Call ratio
-
0%
-
Number of buys
-
27
-
Number of sells
-
-14
-
Price
-
$3.59
Significant Holders of Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) as of Q4 2022
57 filings reported holding SYRS - Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share as of Q4 2022.
Syros Pharmaceuticals, Inc. - Common Stock, $0.001 par value per share (SYRS) has 51 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 10,562,398 shares
of 27,196,692 outstanding shares and own 38.84% of the company stock.
Largest 10 shareholders include Bain Capital Life Sciences Investors, LLC (2,124,694 shares), Artal Group S.A. (1,463,829 shares), Flagship Pioneering Inc. (993,848 shares), Avidity Partners Management LP (900,000 shares), Samsara BioCapital, LLC (881,450 shares), Ally Bridge Group (NY) LLC (868,403 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (721,914 shares), VANGUARD GROUP INC (472,730 shares), CVI Holdings, LLC (425,500 shares), and Altium Capital Management LP (315,070 shares).
This table shows the top 51 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.